MHLW Orders Additional Adverse Effect To Bayer’s Nexavar
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare has ordered Bayer Healthcare to add a serious adverse effect to cancer drug Nexavar (sorafenib) upon receiving reports that after taking the drug, four patients have developed interstitial pneumonia, and among them two died of the disease. Approved by the MHLW in April 2008, sorafenib was launched to the market with an indication to treat progressive kidney cell cancer. There are 2,000 patients who are taking the drug in Japan. (Click here for more - Japanese language